Incyte Corporation Draws Bullish Options Activity Today

 Incyte Corporation Draws Bullish Options Activity Today

In today’s session Incyte Corporation (INCY) registered an unusually high (177) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the December, 2016 call, expecting serious INCY increase. With 177 contracts traded and 1194 open interest for the Dec, 16 contract, it seems this is a quite bullish bet. The option with symbol: INCY161216C00130000 closed last at: $0.5 or 42.9% up. The stock closed at $106.8 during the last session. It is down 39.12% since April 22, 2016 and is uptrending. It has outperformed by 33.71% the S&P500.

Analysts await Incyte Corporation (NASDAQ:INCY) to report earnings on February, 9. They expect $0.18 earnings per share, down 37.93% or $0.11 from last year’s $0.29 per share. INCY’s profit will be $33.51M for 148.33 P/E if the $0.18 EPS becomes a reality. After $0.11 actual earnings per share reported by Incyte Corporation for the previous quarter, Wall Street now forecasts 63.64% EPS growth.

Incyte Corporation (NASDAQ:INCY) Ratings Coverage

Out of 19 analysts covering Incyte (NASDAQ:INCY), 17 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 89% are positive. Incyte has been the topic of 39 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Friday, February 12 by Brean Capital. The stock has “Outperform” rating given by Raymond James on Thursday, September 29. As per Tuesday, October 6, the company rating was maintained by Nomura. The firm earned “Outperform” rating on Thursday, November 12 by Leerink Swann. Argus Research maintained the shares of INCY in a report on Tuesday, August 18 with “Buy” rating. As per Friday, August 5, the company rating was initiated by Suntrust Robinson. The stock of Incyte Corporation (NASDAQ:INCY) has “Buy” rating given on Wednesday, November 4 by UBS. On Wednesday, October 5 the stock rating was maintained by Jefferies with “Hold”. The stock of Incyte Corporation (NASDAQ:INCY) has “Outperform” rating given on Tuesday, February 16 by Leerink Swann. Argus Research maintained the stock with “Buy” rating in Monday, September 26 report.

According to Zacks Investment Research, “Incyte Corp is a drug discovery company that is using its expertise in genomics, medicinal chemistry and molecular, cellular and in vivo biology to discover and develop novel therapeutics. The company has three fully-staffed drug discovery programs underway focused primarily on the identification of new small molecule drugs for cancer and inflammation. Incyte also has strategic alliances with Lexicon Genetics and Medarex focused on the discovery and development of protein therapeutics or antibodies to treat inflammatory diseases and cancer.”

Insitutional Activity: The institutional sentiment decreased to 1.15 in Q2 2016. Its down 0.04, from 1.19 in 2016Q1. The ratio dropped, as 32 funds sold all Incyte Corporation shares owned while 116 reduced positions. 45 funds bought stakes while 131 increased positions. They now own 172.01 million shares or 5.11% less from 181.27 million shares in 2016Q1.
Walleye Trading last reported 1,500 shares in the company. Ellington Mgmt Group Ltd Liability accumulated 0.37% or 3,300 shares. Morgan Stanley accumulated 0.01% or 409,939 shares. Fuller & Thaler Asset Mngmt holds 0% or 1,300 shares in its portfolio. Axa has 473,118 shares for 0.17% of their US portfolio. Moreover, Qs Invsts Ltd Company has 0% invested in Incyte Corporation (NASDAQ:INCY) for 3,517 shares. Brown Advisory Incorporated last reported 0.02% of its portfolio in the stock. Alyeska Inv Group Lp last reported 0.41% of its portfolio in the stock. Employees Retirement Association Of Colorado last reported 0.02% of its portfolio in the stock. State Board Of Administration Of Florida Retirement System last reported 0.06% of its portfolio in the stock. Eqis Capital Management has 0.16% invested in the company for 28,649 shares. California State Teachers Retirement Systems has invested 0.06% of its portfolio in Incyte Corporation (NASDAQ:INCY). Hbk Investments Ltd Partnership accumulated 16,838 shares or 0.01% of the stock. Timber Hill Lc holds 0% of its portfolio in Incyte Corporation (NASDAQ:INCY) for 3,486 shares. Frontier Cap Mgmt Ltd Liability Corp has invested 0.53% of its portfolio in Incyte Corporation (NASDAQ:INCY).

Insider Transactions: Since July 29, 2016, the stock had 0 buys, and 8 sales for $13.79 million net activity. 10,000 Incyte Corporation (NASDAQ:INCY) shares with value of $900,000 were sold by SWAIN PAULA J. Another trade for 10,000 shares valued at $879,600 was made by Huber Reid M on Tuesday, August 2. 24,204 Incyte Corporation (NASDAQ:INCY) shares with value of $2.35 million were sold by Flannelly Barry P.

Incyte Corporation is a biopharmaceutical company. The company has a market cap of $19.88 billion. The Firm is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. It has a 142.9 P/E ratio. The Firm focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases .

INCY Company Profile

Incyte Corporation, incorporated on April 8, 1991, is a biopharmaceutical company. The Firm is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. The Firm focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases (JAK). The Company’s pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI (ruxolitinib). The Firm has discovered multiple potent, selective and orally bioavailable JAK inhibitors that are selective for JAK1 or JAK1 and JAK2. JAKAFI is the compound in its JAK program, which is an oral JAK1 and JAK2 inhibitor. JAKAFI orphan drug is indicated for Myelofibrosis (MF), Polycythemia Vera (PV) and essential thrombocythemia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment